Anthony Silva is co-host of the WBZ Afternoon News heard each weekday from 3:00pm-8:00pm and he is also the station’s New England Business Editor. Silva produces 50 New England Business Reports each week which are heard weekday mornings and afternoons on WBZ NewsRadio 1030. Over the years, Silva has interviewed hundreds of CEO’s, entrepreneurs, economists, inventors, and other experts in the only broadcast series in Boston that exclusively focuses on business, technology, and medical developments in our region.
In addition, Silva produces the daily WBZ “MarketWrap,” providing the closing stock numbers for the largest employers in Massachusetts. Each afternoon, Anthony presents “The New England Small Business Report,” focusing on the area’s often overlooked micro and smaller companies and start-ups. Silva also hosts the daily “Money Matters” segment with Certified Financial Planner, Educator and Author, Dee Lee.
Silva originated and hosts the WBZ Business Breakfast Series, offering three programs per year as a free, public service for WBZ listeners. Over the course of two decades, Silva has welcomed dozens of business leaders, politicians, authors, and experts to live audiences in Boston for open discussions on topical business-oriented issues. Previous featured speakers include: Sir Richard Branson, Jack Welch, Katie Couric, George Stephanopoulos, Rosebeth Moss Kanter, Jeanne Shaheen, Jim Koch, Paul Sagan, John Henry, Bert Jacobs and many others.
During his years at WBZ NewsRadio 1030, Silva has won numerous awards including the Champion Media Award for Economic Understanding, The Small Business Administration’s Reporter of the Year, the Ohio State Award, and numerous AP and Tom Phillips Awards for best newscast, best breaking news story, best feature and best reporter. Silva has reported on breaking news, political and business events from all over the country, from Europe, Latin America and Southeast Asia.
Silva has been a featured speaker, host and master of ceremonies for many business groups, fraternal organizations and colleges, including: Harvard University, Endicott College, The Federal Home Loan Bank of Boston, The Greater Boston Chamber of Commerce, The AARP Business Leaders Forum, Associated Industries of Massachusettts, Financial Executives International, the Massachusetts Rehabilitation Commission, Initiative for a New Economy and others.
Silva has also narrated Copeland’s “Lincoln Portrait” and three performances of Prokofiev’s “Peter and the Wolf” with the Symphony by the Sea. Silva graduated from Emerson College and lives on the North Shore coast with his wife. He is an avid sailor and cyclist who has completed two centuries.
Shares of iRobot gained more than 7% Monday, after the Bedford company announced its newest video collaboration robot is ready for delivery.
Peter Leeds, author of Penny Stocks for Dummies, has major concerns about the currency in the aftermath of the Mt Gox Bitcoin fiasco.
“Hank” has been investing in Bitcoin for years. He says there’s been a lot of bad news around the digital currency lately.
The Italian bakery in Boston’s North End has received unanimous approval from the Cambridge Board of Zoning Appeal to open in Harvard Square.
A 30-year-old Billerica precision manufacturer will be staying put. Its senior leadership led a leveraged buyout of the company, saving local jobs.
Berklee College of Music is launching the Institute for Creative Entrepreneurship as a new initiative to foster the best practices of business and technology in the music business.
EnVivo Pharmaceuticals of Watertown is about to begin new tests on a promising treatment for Alzheimer’s Disease.
A medical conference in San Francisco is still buzzing in reaction to some positive clinical results from a Cambridge biotech which is trying to attack a disease that kills children.
The number of complaints about credit card companies is growing, but more of those complaints are being resolved.
Genzyme is spending $700 million dollars to buy a chunk of Alnylam Pharmaceuticals of Cambridge — a much smaller company that been moving rapidly toward commercializing treatments for rare genetic diseases.